Strategic Partnership to Enhance T Cell Therapies
CellFE and Made Scientific have joined forces in a groundbreaking collaboration to elevate the field of non-viral gene editing, aiming to make strides in T cell therapies. This partnership focuses on utilizing CellFE's innovative High Volume Cyva™ System, paving the way for advanced cell therapies that have the potential to transform patient care.
Innovative Approaches to Gene Editing
The partnership's main endeavor is to pilot two distinctive manufacturing workflows. One approach utilizes activated T cells, combining both non-viral and viral gene editing methods to create personalized autologous T cell products swiftly. This strategy responds to the growing demand for tailored immunotherapies that match individual patient needs, thus providing a more effective treatment option.
The second approach centers on resting or quiescent T cells, a novel concept that aims to break new ground in creating viable allogeneic T cell therapies. By proving the concept for a reliable allogeneic resting T cell therapeutic approach, this collaboration has the potential to develop off-the-shelf cell therapy solutions, leading to faster access and reduced treatment delays for patients.
Role of CellFE and Made Scientific
Within this partnership, CellFE has entrusted Made Scientific to execute pilot-scale studies using their cutting-edge High Volume Cyva™ System. This partnership leverages Made Scientific’s advanced manufacturing capabilities and extensive expertise in cell therapy process development. The goal is to validate the capability of CellFE’s microfluidics technology in maintaining cell health and maximizing yields while enabling sophisticated genome editing without using viral vectors.
As highlighted by Alla Zamarayeva, Ph.D., CEO and Co-founder of CellFE, this collaboration is geared to redefine the benchmarks of engineered T cell therapy manufacturing. Their joined efforts will provide essential data to support the scaling of this technology for clinical use.
Expert Insights from Made Scientific
Syed T. Husain, Chairman & CEO of Made Scientific, remarked on the collaboration's promise. By merging the specialties of their T cell manufacturing platform with CellFE’s groundbreaking microfluidics technology, they aim to significantly boost quality and expedite timelines while addressing the distinct needs of these revolutionary therapies.
Future Developments and Expectations
As they progress, the results from this pilot program will be compiled into a comprehensive white paper slated for presentation to the cell and gene therapy community. This document is expected to share insights and findings that emerge from their research, contributing to the broader knowledge base of the sector.
About CellFE
CellFE stands at the forefront of microfluidics technology, dedicated to transforming how life-saving cell therapies are developed and manufactured. With a commitment to addressing key obstacles within the market, such as high production costs and lengthy timelines, CellFE is poised to revolutionize the domain with its microfluidics-based gene delivery technology. Their solutions specifically target T-cell, HSC, and iPSC therapies, aiming to streamline manufacturing processes and improve patient access to advanced therapies.
About Made Scientific
Made Scientific specializes in the development and manufacturing of cell therapy products, establishing itself as a vital player within the CDMO landscape since its inception. Focused on both autologous and allogeneic therapies, the company operates from two manufacturing facilities in the U.S., combining the agility of a specialized CDMO with the robust resources of its parent organization, GC Corporation.
Through this collaboration, both companies are eager to navigate the complexities of cell therapy, setting the stage for innovations that could significantly advance treatment options for patients globally.
Frequently Asked Questions
What is the purpose of the strategic collaboration?
The collaboration aims to advance non-viral gene editing techniques for T cell therapies and develop pilot data using CellFE's High Volume Cyva™ System.
What unique approaches are being evaluated?
Two workflows are being tested: one involving activated T cells for personalized treatments, and another focusing on resting T cells for allogeneic therapies.
Who is responsible for conducting the studies?
Made Scientific has been selected by CellFE to carry out the pilot-scale studies leveraging their advanced manufacturing capabilities.
What is expected from the results of the pilot program?
The results will be communicated in a white paper shared with the cell and gene therapy community to further knowledge in the field.
How does CellFE’s technology impact cell therapy?
CellFE’s microfluidics technology aims to enhance cell health, maximize yields, and streamline the genome editing process, ultimately improving the delivery of advanced therapies to patients.
